CN116917478A - Crispr/cas13在rna病毒和/或细菌诱导的疾病的治疗中的应用 - Google Patents

Crispr/cas13在rna病毒和/或细菌诱导的疾病的治疗中的应用 Download PDF

Info

Publication number
CN116917478A
CN116917478A CN202180094344.1A CN202180094344A CN116917478A CN 116917478 A CN116917478 A CN 116917478A CN 202180094344 A CN202180094344 A CN 202180094344A CN 116917478 A CN116917478 A CN 116917478A
Authority
CN
China
Prior art keywords
composition
grna
protein
cas13
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180094344.1A
Other languages
English (en)
Chinese (zh)
Inventor
C·格鲁伯
D·J·J·特隆
F·吉泽特
W·伍斯特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helmholtz Munich Center German Center For Health And Environmental Research Ltd
Original Assignee
Helmholtz Munich Center German Center For Health And Environmental Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Helmholtz Munich Center German Center For Health And Environmental Research Ltd filed Critical Helmholtz Munich Center German Center For Health And Environmental Research Ltd
Publication of CN116917478A publication Critical patent/CN116917478A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202180094344.1A 2020-12-22 2021-12-21 Crispr/cas13在rna病毒和/或细菌诱导的疾病的治疗中的应用 Pending CN116917478A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
LULU102326 2020-12-22
LU102326 2020-12-22
PCT/EP2021/086992 WO2022136370A1 (en) 2020-12-22 2021-12-21 Application of crispr/cas13 for therapy of rna virus and/or bacterium induced diseases

Publications (1)

Publication Number Publication Date
CN116917478A true CN116917478A (zh) 2023-10-20

Family

ID=74626052

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180094344.1A Pending CN116917478A (zh) 2020-12-22 2021-12-21 Crispr/cas13在rna病毒和/或细菌诱导的疾病的治疗中的应用

Country Status (6)

Country Link
US (1) US20240041990A1 (https=)
EP (1) EP4267736A1 (https=)
JP (1) JP2024500932A (https=)
CN (1) CN116917478A (https=)
CA (1) CA3203046A1 (https=)
WO (1) WO2022136370A1 (https=)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
EP1025217B1 (en) 1997-10-24 2006-10-04 Invitrogen Corporation Recombinational cloning using nucleic acids having recombination sites
US10056224B2 (en) 2015-08-10 2018-08-21 Kla-Tencor Corporation Method and system for edge-of-wafer inspection and review
CA3028158A1 (en) * 2016-06-17 2017-12-21 The Broad Institute, Inc. Type vi crispr orthologs and systems
CN111108220B (zh) * 2017-03-15 2024-11-19 博德研究所 用于病毒检测的基于crispr效应系统的诊断
AU2018234825B2 (en) * 2017-03-15 2020-12-17 Massachusetts Institute Of Technology Novel CAS13B orthologues CRISPR enzymes and systems
US11168322B2 (en) * 2017-06-30 2021-11-09 Arbor Biotechnologies, Inc. CRISPR RNA targeting enzymes and systems and uses thereof
WO2019010422A1 (en) * 2017-07-07 2019-01-10 The Broad Institute, Inc. ANTIVIRAL THERAPY BASED ON THE CRISPR SYSTEM
WO2019018423A1 (en) * 2017-07-17 2019-01-24 The Broad Institute, Inc. NEW TYPE VI CRISPR ORTHOLOGISTS AND ASSOCIATED SYSTEMS
US10476825B2 (en) * 2017-08-22 2019-11-12 Salk Institue for Biological Studies RNA targeting methods and compositions
CN107939288B (zh) 2017-11-14 2019-04-02 中国科学院地质与地球物理研究所 一种非旋转套的防转装置以及旋转导向装置
CN113348245A (zh) * 2018-07-31 2021-09-03 博德研究所 新型crispr酶和系统
US12258594B2 (en) * 2018-12-05 2025-03-25 The Broad Institute, Inc. Cas proteins with reduced immunogenicity and methods of screening thereof
CN110656123B (zh) * 2019-10-12 2021-07-13 中国农业大学 基于CRISPR-Cas13d系统的sgRNA高效作用靶点的筛选方法及应用

Also Published As

Publication number Publication date
WO2022136370A1 (en) 2022-06-30
CA3203046A1 (en) 2022-06-30
JP2024500932A (ja) 2024-01-10
EP4267736A1 (en) 2023-11-01
US20240041990A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
CA3231909A1 (en) Engineered casx repressor systems
JP2023514149A (ja) リボザイムにより媒介されるｒｎａアセンブリ及び発現
US20250223614A1 (en) Synthetic polypeptides and uses thereof
AU2019234917B2 (en) Inhibitors of micro-RNA 22
CN111133107A (zh) 用于治疗性核酸递送的跨界平台
US20240376468A1 (en) CIRCULAR GUIDE RNAs FOR CRISPR/CAS EDITING SYSTEMS
CA3226664A1 (en) Guide rnas for crispr/cas editing systems
US20170233742A1 (en) Compositions Comprising Small Interfering RNA Molecules for Prevention and Treatment of Ebola Virus Disease
CN101880677B (zh) 针对2009新甲型流感病毒多聚酶基因和核蛋白基因的siRNA序列及其应用
CN116917478A (zh) Crispr/cas13在rna病毒和/或细菌诱导的疾病的治疗中的应用
JP2024532019A (ja) アルファ－１アンチトリプシン発現を阻害するための組成物及び方法
KR102839248B1 (ko) Cas13 단백질 및 crRNA를 포함하는 코로나바이러스감염증-19 예방 또는 치료용 약학적 조성물
US20250382599A1 (en) Viral load-dependent crispr/cas13-system
KR101070654B1 (ko) 중증급성호흡기증후군 코로나바이러스(ｓｃｖ)에 대한 저해활성을 가지는 조성물
JP2025523992A (ja) 細胞におけるゲノム挿入
JP2004525602A (ja) 組織特異的および病原菌特異的毒性剤、リボザイム、ＤＮＡｚｙｍｅおよびアンチセンスオリゴヌクレオチドとそれらの使用方法
CN117838832B (zh) Rbm25及其相关物质在抗病毒感染中的应用
US20230181613A1 (en) Inhibitors of micro-rna 22
US20260002151A1 (en) Compositions and methods for the modification and regulation of liver gene expression
US20240409945A1 (en) RNAi TARGETING PPP2R5D MISSENSE MUTATIONS FOR TREATMENT OF JORDAN’S SYNDROME
JP2026509506A (ja) リボザイム媒介ｒｎａアセンブリおよび発現
US20100286238A1 (en) Suppression of viruses involved in respiratory infection or disease
US20240409937A1 (en) RNAi TARGETING HNRNPH2 MISSENSE MUTATIONS FOR TREATMENT OF BAIN SYNDROME
TW202545541A (zh) 上調端粒酶的多核苷酸及其用途和治療方法
EP1702983A2 (en) Tissue-specific and pathogen-specific toxic agents, ribozymes, DNAzymes and antisense oligonucleotides and methods of use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination